Still in the process of integration, Mallinckrodt is preparing to build its launch structure in Canada. With several innovative products in the pipeline, Robin Hunter, general manager of Canadian operations, highlights the company’s ambition to be a top tier innovative specialty pharma company with a specific area of focus in hospital-based therapies and rare diseases.
Robin, can you please give our readers a brief overview of Mallinckrodt’s recent evolution and its operations in Canada?
"One of the challenges I am facing when trying to implement the build out of our Canadian affiliate is to determine a balance between leveraging shared services from the US, building our own capabilities in Canada and outsourcing to partners."
